Roche Claims 'Other Options' If Illumina Deal Fails

Mar 06, 2012

NEW YORK (GenomeWeb News) – Roche Chairman Franz Humer today said that the firm has "other options" if its bid to acquire Illumina fails.

Humer's statement was part of prepared remarks made for Roche's annual general meeting, held today in Basel, Switzerland, where the firm is based.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Featured White Papers

IBM Platform Computing Cloud Service for BIOVIA NGS Workflow

Main menu